2021年5月25日
SOMERSET, N.J., May 25, 2021 – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced it will present at the Jefferies Virtual Healthcare Conference on June 3, 2021 at 9:30 am ET. This webcast will b available to investors and other interested parties by accessing the Legend Biotech website at https://investors.legendbiotech.com
About Legend Biotech
Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 800 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture best-in-class cell therapies for patients in need.
We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, cilta-cel, an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. This candidate is currently being studied in registrational clinical trials.
For Media and Investor Relations inquiries, please contact:
Jessie Yeung, Head of Corporate Finance and Investor Relations, Legend Biotech jessie.yeung@legendbiotech.com or investor@legendbiotech.com
Crystal Chen, Manager of Investor Relations and Corporate Communications, Legend Biotech crystal.chen@legendbiotech.com or media@legendbiotech.com
欧盟委员会批准 CARVYKTI®用于复发和难治性多发性骨髓瘤患者的二线..
2024年4月23日
传奇生物CARVYKTI®成为首个且唯一获FDA批准用于多发性骨髓瘤二线治..
2024年4月5日
传奇生物发布首份环境、社会和管治(ESG)报告
2024年3月19日
CARVYKTI®获得美国FDA肿瘤药物咨询委员会用于复发或难治性多发性骨..
2024年3月16日
传奇生物公布2023年全年及第四季度业绩及近期亮点
2024年3月11日
传奇生物获得CHMP对CARVYKTI®用于前线治疗的积极意见
2024年2月23日